• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A review of economic evaluation in osteoporosis.

作者信息

Cranney A, Coyle D, Welch V, Lee K M, Tugwell P

机构信息

Department of Medicine, Loeb Research Unit, Ottawa Hospital, Ontario, Canada.

出版信息

Arthritis Care Res. 1999 Dec;12(6):425-34. doi: 10.1002/1529-0131(199912)12:6<425::aid-art11>3.0.co;2-a.

DOI:10.1002/1529-0131(199912)12:6<425::aid-art11>3.0.co;2-a
PMID:11081014
Abstract
摘要

相似文献

1
A review of economic evaluation in osteoporosis.骨质疏松症的经济评估综述
Arthritis Care Res. 1999 Dec;12(6):425-34. doi: 10.1002/1529-0131(199912)12:6<425::aid-art11>3.0.co;2-a.
2
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis.评估骨质疏松症治疗和预防成本效益的模型
Osteoporos Int. 2002 Nov;13(11):841-57. doi: 10.1007/s001980200117.
3
Treatment of established osteoporosis: a systematic review and cost-utility analysis.已确诊骨质疏松症的治疗：一项系统评价与成本效益分析。
Health Technol Assess. 2002;6(29):1-146. doi: 10.3310/hta6290.
4
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.开发和验证用于骨质疏松症治疗经济评估的马尔可夫微模拟模型。
Value Health. 2009 Jul-Aug;12(5):687-96. doi: 10.1111/j.1524-4733.2008.00497.x.
5
Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.基于人群的骨质疏松症干预对非创伤性非髋部骨折门诊患者的经济学评价：“抓住机会”1i [类型 C] FLS。
Osteoporos Int. 2017 Jun;28(6):1965-1977. doi: 10.1007/s00198-017-3986-3. Epub 2017 Mar 9.
6
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.骨质疏松症治疗与预防的成本效益——文献综述及参考模型
Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9.
7
Cost-effectiveness of hormone therapy in the United States.美国的激素治疗的成本效益。
J Womens Health (Larchmt). 2009 Oct;18(10):1669-77. doi: 10.1089/jwh.2008.1246.
8
Hormone replacement therapy: a review of the risk versus benefit--Part II.
Med Interface. 1997 Jan;10(1):108-14.
9
Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.骨质疏松症筛查及治疗的成本效益：药物依从性的影响。
Value Health. 2010 Jun-Jul;13(4):394-401. doi: 10.1111/j.1524-4733.2009.00687.x. Epub 2010 Jan 21.
10
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.骨质疏松症经济评估实施建议：由欧洲临床与经济骨质疏松症、骨关节炎和肌肉骨骼疾病学会（ESCEO）和国际骨质疏松基金会美国分会组织的专家共识会议的结果。
Osteoporos Int. 2019 Jan;30(1):45-57. doi: 10.1007/s00198-018-4744-x. Epub 2018 Oct 31.

引用本文的文献

1
Association between renin-angiotensin-aldosterone system blockade and future osteoporotic fracture risk in hypertensive population: A population-based cohort study in Taiwan.肾素-血管紧张素-醛固酮系统阻断与高血压人群未来骨质疏松性骨折风险的关联：台湾一项基于人群的队列研究
Medicine (Baltimore). 2017 Nov;96(46):e8331. doi: 10.1097/MD.0000000000008331.
2
Quality of life measurements in patients with osteoporosis and fractures.骨质疏松症和骨折患者的生活质量测量。
Clinics (Sao Paulo). 2012 Nov;67(11):1315-20. doi: 10.6061/clinics/2012(11)16.
3
The need for microsimulation to evaluate osteoporosis interventions.
评估骨质疏松症干预措施的微观模拟需求。
Osteoporos Int. 2005 Apr;16(4):353-8. doi: 10.1007/s00198-004-1826-8. Epub 2005 Jan 11.
4
Quality of life in patients with osteoporosis.骨质疏松症患者的生活质量。
Osteoporos Int. 2005 May;16(5):447-55. doi: 10.1007/s00198-004-1762-7. Epub 2004 Dec 18.
5
Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.
Pharmacoeconomics. 2001;19(5 Pt 2):565-75. doi: 10.2165/00019053-200119050-00010.